Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Pharmacogenomics and Laboratory Medicine
139
Roy, J.N., Lajoie, J., Zijenah, L.S., Barama, A., Poirier, C., Ward, B.J., and Roger, M. (2005).
CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metabolism
and Disposition 33, 884–887.
Sachidanandam, R., Weissman, D., Schmidt, S.C., Kakol, J.M., Stein, L.D., Marth, G.,
Sherry, S., et al. (2001). A map of human genome sequence variation containing
1.42 million single nucleotide polymorphisms. Nature 409, 928–933.
Sanderson, S., Emery, J., and Higgins, J. (2005). CYP2C9 gene variants, drug dose, and
bleeding risk in warfarin-treated patients: A HuGEnet systematic review and metaanalysis.
Genetics in Medicine 7, 97–104.
Sanger, F., Air, G.M., Barrell, B.G., Brown, N.L., Coulson, A.R., Fiddes, C.A., Hutchison, C.A.,
Slocombe, P.M., and Smith, M. (1977a). Nucleotide sequence of bacteriophage phi
X174 DNA. Nature 265, 687–695.
Sanger, F., Nicklen, S., and Coulson, A.R. (1977b). DNA sequencing with chain-terminating
inhibitors. Proceedings of the National Academy of Sciences of the United States of
America 74, 5463–5467.
Santos, P.C., Soares, R.A., Nascimento, R.M., Machado-Coelho, G.L., Mill, J.G., Krieger, J.E.,
and Pereira, A.C. (2011). SLCO1B1 rs4149056 polymorphism associated with statininduced
myopathy is differently distributed according to ethnicity in the Brazilian general
population: Amerindians as a high risk ethnic group. BMC Medical Genetics 12, 136.
Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.S., Johnson, J.A., Roden, D.M.,
Klein, T.E., Shuldiner, A.R., and Clinical Pharmacogenetics Implementation
Consortium. (2011). Clinical Pharmacogenetics Implementation Consortium guidelines
for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical
Pharmacology and Therapeutics 90, 328–332.
Shannon, K.M., and Chittenden, A. (2012). Genetic testing by cancer site: Breast. Cancer
Journal 18, 310–319.
Shinmura, K., Kageyama, S., Tao, H., Bunai, T., Suzuki, M., Kamo, T., Takamochi, K., et al.
(2008). EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-
ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61, 163–169.
Shiota, M., Nakamura, S., Ichinohasama, R., Abe, M., Akagi, T., Takeshita, M., Mori, N.,
et al. (1995). Anaplastic large cell lymphomas expressing the novel chimeric protein
p80NPM/ALK: A distinct clinicopathologic entity. Blood 86, 1954–1960.
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987).
Human breast cancer: Correlation of relapse and survival with amplification of the
HER-2/neu oncogene. Science 235, 177–182.
Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.,
et al. (2007). Identification of the transforming EML4-ALK fusion gene in nonsmall-cell
lung cancer. Nature 448, 561–566.
Song, J., Mercer, D., Hu, X., Liu, H., and Li, M.M. (2011). Common leukemia- and
lymphoma-associated genetic aberrations in healthy individuals. The Journal of
Molecular Diagnostics 13, 213–219.
Spear, B.B., Heath-Chiozzi, M., and Huff, J. (2001). Clinical application of pharmacogenetics.
Trends in Molecular Medicine 7, 201–204.
Strassburg, C.P. (2008). Pharmacogenetics of Gilbert’s syndrome. Pharmacogenomics 9,
703–715.
Sullivan-Klose, T.H., Ghanayem, B.I., Bell, D.A., Zhang, Z.Y., Kaminsky, L.S., Shenfield, G.M.,
Miners, J.O., Birkett, D.J., and Goldstein, J.A. (1996). The role of the CYP2C9-Leu359
allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341–349.
Tai, H.L., Krynetski, E.Y., Yates, C.R., Loennechen, T., Fessing, M.Y., Krynetskaia, N.F., and
Evans, W.E. (1996). Thiopurine S-methyltransferase deficiency: Two nucleotide transitions
define the most prevalent mutant allele associated with loss of catalytic activity in
Caucasians. American Journal of Human Genetics 58, 694–702.